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Despite stringent requirements for drug
development imposed by regulatory agen-
cies, drug-induced liver injury (DILI) is
an increasing health problem and a signif-
icant cause for failure to approve drugs,
market withdrawal of commercialized
medications, and adoption of regula-
tory measures. The pathogenesis is yet
undefined, though the rare occurrence of
idiosyncratic DILI (1/100,000–1/10,000)
and the fact that hepatotoxicity often
recurs after re-exposure to the culprit
drug under different environmental con-
ditions strongly points toward a major
role for genetic variations in the under-
lying mechanism and susceptibility.
Pharmacogenetic studies in DILI have
to a large extent focused on genes involved
in drug metabolism, as polymorphisms
in these genes may generate increased
plasma drug concentrations as well as
lower clearance rates when treated with
standard medication doses. A range of
studies have identified a number of genetic
variants in drug metabolism Phase I,
II, and III genes, including cytochrome
P450 (CYP) 2E1, N-acetyltransferase 2,
UDP-glucuronosyltransferase 2B7, glu-
tathione S-transferase M1/T1, ABCB11,
and ABCC2, that enhance DILI suscep-
tibility (Andrade et al., 2009; Agundez
et al., 2011). Several metabolic gene vari-
ants, such as CYP2E1c1 and NAT2 slow,
have been associated with DILI induced
by specific drugs based on individual
drug metabolism information. Others,
such as GSTM1 and T1 null alleles have
been associated with enhanced risk of
DILI development induced by a large
range of drugs. Hence, these variants
appear to have a more general role in
DILI susceptibility due to their role in
reducing the cell’s antioxidative capac-
ity (Lucena et al., 2008). Mitochondrial
superoxide dismutase (SOD2) and glu-
tathione peroxidase 1 (GPX1) are two
additional enzymes involved in com-
bating oxidative stress, with specific
genetic variants shown to enhance the
risk of developing DILI (Lucena et al.,
2010).
Nevertheless, there are discrepancies in
the findings and many studies are based
on small cohorts and subsequently insuf-
ficient to confirm a prominent associa-
tion between genetic variability in drug
metabolism and the risk of DILI. It is
important to note that interethnic dif-
ferences in allele frequency are present
and should be considered as a source
of heterogeneity when analysing diverse
ethnicities. In addition, populations with
low variant allele frequencies require high
sample sizes to achieve adequate statis-
tical power. Although significant associ-
ations between specific drug metabolism
gene variants and DILI susceptibility have
been found, the low relative risk associated
with these variants prevents clinical trans-
lation, such as the development of pre-
dictive biomarkers (Agundez et al., 2012).
Screening for specific risk genotypes iden-
tified to date prior to prescriptions would
not adequately reduce the number of DILI
incidents and could also prevent treatment
for many risk allele carriers that would
not develop DILI if taking the specific
drug.
The introduction of genome-wide
association (GWA) studies brought
great expectations for the revelation of
genetic components responsible for DILI
susceptibility. Unfortunately, the out-
come has yet not reached the anticipated
results. Despite the wide coverage of vari-
ants across the entire genome with this
technique, none of the previously iden-
tified drug metabolizing gene variants
has been confirmed. In fact, only spe-
cific human leukocyte antigen (HLA)
alleles have been significantly associated
with idiosyncratic DILI in the GWA stud-
ies performed to date (Daly, 2012). The
HLA genes are located in the major his-
tocompatibility complex (MHC) region
on chromosome 6 and play a prominent
role in the human immune system. The
class I and II HLA genes encodes for cell
surface antigen presenting proteins while
the class III derived proteins have variable
functions, such as comprising the com-
plement system. The class I and II genes
display a large degree of polymorphisms.
This variability stems from the need to
successfully display a wide range of pro-
cessed foreign peptides to T cell antigen
receptors.
The lack of drug metabolizing gene
associations could be due to limitations
of the GWA technique as several factors
restricting the GWA utility have been
identified: (1) very rare genetic variants
with very weak effects are not detectable
by stringent statistical association analy-
ses, (2) a high number of variants may be
present for the same gene with different
effects on protein function and the com-
bination of variants may be even more
complex in multifactorial diseases, such
as DILI, (3) phenotypic diversity in DILI
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cohorts may “dilute” the presence of spe-
cific genetic variations, (4) incomplete
coverage of the genome due to technical
performance or to variations in linkage
disequilibrium strength between single
nucleotide polymorphisms (SNPs) in the
tested population and the population used
to design the array, (5) systemic errors
due to differences in variant frequencies
between different ethnicities, (6) geo-
graphic diversity within the same ethnicity
may lead to population-specific effects
that, if not accounted for, may prevent
identification of disease variants (Karlsen
et al., 2010). The last point is particularly
important in terms of DILI. Due to the
relative rarity of this condition, a single
center is unlikely to obtain sufficient cases
for successful studies. Collaborative efforts
are therefore needed to reach a high num-
ber of cases, which can come at the expense
of population differences. In addition to
array based GWA studies, whole-genome
sequencing is fast approaching as a means
of searching for genetic variations that
contribute to medical conditions. The
introduction of “next generation sequenc-
ing technologies” has led to a dramatic
fall in sequencing cost and together
with the increase in genetic information
obtained, compared to more conventional
array based techniques, whole-genome
sequencing offers an enormous potential.
Nevertheless, whole-genome sequencing is
not without bioinformatic and analytical
challenges and its usefulness in person-
alized medicine will require concerted
efforts between multiple groups in a wide
range of disciplines (Cordero and Ashley,
2012).
Genetic heterogeneity is common in
complex diseases, which points toward a
likelihood of multiple genes and pathways
being implicated in DILI development.
Changes in any of these genes or path-
ways may lead to the same phenotype,
which complicates the identification of
specific genetic risk factors. Moreover, the
genetic redundancy existing in the human
genome may very well compensate for the
disruption of a single gene and conse-
quently lead to a neutral effect. A combi-
nation of genetic variants affecting several
genes simultaneously may therefore be
required to produce a specific phenotype
or cellular environment in which the pres-
ence of an interfering drug compound
could lead to DILI. Hence, the impor-
tance here is not the individual variants
per se but the resulting cellular pheno-
type, which could be reached through var-
ious polymorphic combinations. Future
studies focusing on cellular/metabolic
pathways and variant combinations in
well-characterized cohorts are therefore
needed. GWA studies have a clear advan-
tage here due to their ability to screen
a large number of variants simultane-
ously. However, the statistical side of this
technique is somewhat lagging behind
as single polymorphisms are generally
considered individually, controlling the
overall type I error rate by correcting
for multiple testing. Considering biolog-
ical pathways and variant interactions in
GWA study analyses could potentially lead
to more meaningful results and is cur-
rently being explored (Wang et al., 2010).
This could lead us toward the ultimate
goal in DILI studies, the identification of
genetic risk factors to provide a better
insight into the underlying pathogenesis
and enable the development of new diag-
nostic tools alongwith new safer treatment
strategies.
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